India's Bliss GVS Pharma up on completion of US FDA inspection

Bliss GVS Pharma

15/06/2023 10:41

** Shares of Bliss GVS Pharma  BLIS.NS  rise as much as
4.01% to 83.05 rupees, their highest level since May 11
    ** Co receives establishment inspection report from U.S. FDA
indicating closure of inspection at its  manufacturing facility
in Maharashtra  urn:newsml:reuters.com:*:nFWN3863JQ
    ** U.S. drug regulator assigns classification of "voluntary
active indicated" for the facility
    ** Stock's trading volume at around 647,000 shares as of
3:02 p.m. IST, nearly thrice the 30-day avg - Refinitiv data
    ** BLIS has risen over 10% in 2023 so far compared to 3%
gains in pharma index  .NIPHARM     

 (Reporting by Bharath Rajeswaran in Bengaluru)
 ((bharath.rajeswaran@thomsonreuters.com; +91 9769003463;))